

3. [AMENDED] The [use according to] method of claim 2, wherein the lactadherin or a variant thereof is [of] a variant of lactadherin lacking at least one protein feature chosen from the group consisting of a functional phospholipid binding site [and/or] and a functional integrin binding site.

4. [AMENDED] The [use according to] method of claim 1, wherein [for the stimulation of the] phagocytosis of antigens by dendritic cells is stimulated in the mammal.

5. [AMENDED] The [use according to] method of claim 1, wherein [for the stimulation of the] cross-priming of antigens is stimulated in the mammal.

6. [AMENDED] [The use of lactadherin or a variant thereof, for the preparation of a] A composition for the delivery of a molecule to a dendritic cell comprising a lactadherin or a variant thereof and the molecule to be delivered.

7. [AMENDED] The [use according to] method of any one [of the preceding claims] of claims 1-5, wherein the lactadherin or variant thereof is human lactadherin or a variant thereof.

8. [AMENDED] A composition comprising [lactadherin or a variant thereof in association with a molecule] a compound of the formula L-M, wherein:
L is a lactadherin or a variant of lactadherin;
M is a selected molecule; and
wherein L is associated with M through a covalent or non-covalent linkage.

9. [AMENDED] The composition of claim 8, wherein [said molecule] L is covalently linked to M [associated to the lactadherin or variant thereof].